{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:22:21Z","timestamp":1762431741348},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n            <jats:title>Background and Objective:<\/jats:title>\n            <jats:p>Clozapine is the drug of choice for treatment-resistant schizophrenia. The primary objective of this study was to compare plasma clozapine and <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethylclozapine levels in patients switched between 2 liquid formulations [Denzapine suspension and clozapine oral solution (St George's ZTAS)]. Secondary objectives included comparison of safety, tolerability, and patient acceptability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a noninterventional, observational, prospective follow-up of patients consecutively switched between formulations of clozapine liquid in a large inner-city NHS mental health trust. The authors also performed retrospective analysis of outcomes from patient case notes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The authors identified 43 patients receiving Denzapine suspension in the trust. Data were available for 43 patients switched from Denzapine to clozapine oral solution (St George's ZTAS), among whom, 15 (32%) were excluded from the analysis. Of the 28 patients for whom data were available, the 90% confidence interval for the ratio of mean values for corrected C<jats:sub>min<\/jats:sub> 91.5 (85.2%\u201398.4%) and uncorrected C<jats:sub>min<\/jats:sub> 91.2 (84.4%\u201398.6%) were within the guideline range of bioequivalence (80%\u2013125%). Safety and tolerability profiles were comparable between the 2 formulations (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.10). Patient acceptability was also similar between the brands in most domains. However, there was a taste preference for Denzapine suspension.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>No significant difference in clozapine plasma levels was observed after switching from Denzapine suspension to a recently introduced clozapine solution. This study also highlights the significance of medicinal characteristics such as taste for patient acceptability and compliance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000711","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T16:09:47Z","timestamp":1572019787000},"page":"491-496","source":"Crossref","is-referenced-by-count":10,"title":["Clozapine and Norclozapine Plasma Levels in Patients Switched Between Different Liquid Formulations"],"prefix":"10.1097","volume":"42","author":[{"given":"Ebenezer","family":"Oloyede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubanke","family":"Dzahini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eromona","family":"Whiskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00023210-200721040-00002","article-title":"When should clozapine be initiated in schizophrenia? some arguments for and against earlier use of clozapine","volume":"21","author":"Kerwin","year":"2007","journal-title":"CNS Drugs."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1751-7893.2012.00374.x","article-title":"Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994\u20132010","volume":"7","author":"Couchman","year":"2013","journal-title":"Early Interv Psychiatry."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1192\/bjp.bp.105.017079","article-title":"Generic clozapine: outcomes after switching formulations","volume":"189","author":"Paton","year":"2006","journal-title":"Br J Psychiatry."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0000000000000231","article-title":"Automated analysis of clozapine and morclozapine in human plasma using novel extraction plate technology and flow-injection tandem mass spectrometry","volume":"38","author":"Couchman","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.schres.2015.07.052","article-title":"Glasgow antipsychotic side-effects scale for clozapine-development and validation of a clozapine-specific side-effects scale","volume":"168","author":"Hynes","year":"2015","journal-title":"Schizophr Res."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4088\/JCP.v67n0706","article-title":"Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review","volume":"67","author":"Alessi-Severini","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pharep.2015.08.017","article-title":"Therapeutic equivalence of antipsychotics and antidepressants\u2014a systematic review","volume":"68","author":"Cessak","year":"2016","journal-title":"Pharmacol Rep."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mehy.2013.11.043","article-title":"Clozapine administered once versus twice daily: does it make a difference?","volume":"82","author":"Procyshyn","year":"2014","journal-title":"Med Hypotheses."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40261-012-0004-6","article-title":"Evaluation of bioequivalence between clozapine suspension and tablet formulations : a multiple-dose, fed and fasted study","volume":"32","author":"Glue","year":"2012","journal-title":"Clin Drug Investig."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/FTD.0b013e3181f0a1a2","article-title":"Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex)","volume":"32","author":"Couchman","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","article-title":"Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993\u20132007","volume":"32","author":"Couchman","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/FTD.0000000000000111","article-title":"Therapeutic drug monitoring of clozapine: sampling error as a source of variance","volume":"36","author":"Lee","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0278-5846(01)00291-3","article-title":"Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables","volume":"26","author":"Palego","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-199732020-00001","article-title":"Will routine therapeutic drug monitoring have a place in clozapine therapy?","volume":"32","author":"Freeman","year":"1997","journal-title":"Clin Pharmacokinet."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ajp.151.1.123","article-title":"Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate","volume":"151","author":"Centorrino","year":"1994","journal-title":"Am J Psychiatry."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-199906000-00017","article-title":"Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders","volume":"21","author":"Facciola","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-2000-8355","article-title":"A case of pharmacokinetic interference in comedication of clozapine and valproic acid","volume":"33","author":"Conca","year":"2000","journal-title":"Pharmacopsychiatry."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1192\/bjp.173.4.341","article-title":"Long-term pharmacokinetics of clozapine","volume":"173","author":"Kurz","year":"1998","journal-title":"Br J Psychiatry."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat Outcome Meas."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00228-015-1886-z","article-title":"It is time to review how unlicensed medicines are used","volume":"71","author":"Sutherland","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1345\/aph.10183","article-title":"Converting patients from brand-name clozapine to generic clozapine","volume":"35","author":"Sajbel","year":"2001","journal-title":"Ann Pharmacother."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1345\/aph.1C069","article-title":"Branded versus generic clozapine for treatment of schizophrenia","volume":"37","author":"Makela","year":"2003","journal-title":"Ann Pharmacother."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.appet.2008.05.063","article-title":"Practice does make perfect: a longitudinal look at repeated taste exposure","volume":"51","author":"Williams","year":"2008","journal-title":"Appetite."},{"issue":"suppl 5","key":"R33-20230814","first-page":"4","article-title":"United States Food and Drug Administration requirements for approval of generic drug products","volume":"62","author":"Meyer","year":"2001","journal-title":"J Clin Psychiatry."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"68","DOI":"10.9740\/mhc.2015.03.068","article-title":"A review of the clinical utility of serum clozapine and norclozapine levels","volume":"5","author":"Ellison","year":"2015","journal-title":"Ment Health Clinician."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00131746-200509000-00003","article-title":"Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring","volume":"11","author":"Khan","year":"2005","journal-title":"J Psychiatr Pract."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2004.03.017","article-title":"Plasma clozapine concentration coefficients of variation in a long-term study","volume":"72","author":"Diaz","year":"2005","journal-title":"Schizophr Res."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:31:52Z","timestamp":1692052312000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000711","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}